Global Huntington's disease Treatment Market will reach US$ 1,458.83 Million by 2027. Huntington's Disease (HD) is a hereditary neurodegenerative disease driven by an expansion of a repeating CAG triplet series in the huntingtin gene (HTT) on chromosome 4, which results in a protein with an abnormally long polyglutamine sequence. Moreover, HD is one of a more prominent family of polyglutamine repeat diseases, all of which are neurodegenerative diseases. It is inherited in an autosomal dominant fashion so that each child of an affected parent has a 50% chance of developing the disorder.
Trends Shaping the Global Huntington's Disease Treatment Market Size:
Globally, the rising prevalence of rare genetic disorders amongst the metropolitan population has grown the incidence of Huntington's disease, with key healthcare stakeholders like Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, and others attempting to discover novel medicinal approaches, providing a platform for manufacturers to expand their influence in the global market.